{"id":"W2520616996","doi":"10.1200/jco.2015.33.3_suppl.tps496","title":"Phase 3 randomized, double-blind, controlled study of cabozantinib (XL184) versus placebo in subjects with hepatocellular carcinoma who have received prior sorafenib (CELESTIAL; NCT01908426).","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Cabozantinib; Medicine; Sorafenib; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Oncology; Tolerability; Placebo; Response Evaluation Criteria in Solid Tumors; Discontinuation; Randomized controlled trial; Cancer; Adverse effect; Phases of clinical research; Gastroenterology; Clinical trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002557289,0.002257909,0.003944723,0.0006645657,0.0007182981,0.001115325,0.001225741,0.002441047,0.01047175],"category_scores_gemma":[0.002325836,0.001009388,0.001799363,0.0005471806,0.001586254,0.001374223,0.0004306156,0.003250261,0.001859213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008891746,"about_ca_system_score_gemma":0.001789501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00118464,"about_ca_topic_score_gemma":0.00292899,"domain_scores_codex":[0.9991145,0.0004638178,0.00004640972,0.000171397,0.00007019189,0.000133758],"domain_scores_gemma":[0.9986921,0.0003618126,0.0003367357,0.00009826948,0.0001182853,0.0003927988],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9835618,0.007990456,0.0002589921,0.0003435299,0.0003901008,0.00002913231,0.00003141017,0.0001261175,0.001963717,0.00005169396,0.0006671725,0.004585884],"study_design_scores_gemma":[0.9611555,0.03733253,0.0007056312,0.00001017308,0.0001074693,0.00001597841,0.00001026417,0.0001996739,0.0001395306,0.00006188842,0.000254249,0.000007023695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9601118,0.005366435,0.002310433,0.001353341,0.001481946,0.02185123,0.003506512,0.0006657228,0.003352538],"genre_scores_gemma":[0.9567813,0.002581975,0.004120999,0.002596161,0.0007988258,0.02504132,0.00238067,0.00007999361,0.005618659],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01047175,"threshold_uncertainty_score":0.03503156,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2807922948578121,"score_gpt":0.4341696107003822,"score_spread":0.1533773158425701,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}